They have one thing in common today: They are both mentioned by TheStreet's Adam Feuerstein in his Biotech Stock Mailbag column.
On INO: "The technology upon which the company's vaccine candidates are based is more than 30 years old and has never proven to be effective in clinical trials. INO's management team is exceptionally promotional and 85% of the company's stock is held by retail investors, according to S&P CapitalIQ."
On CHTP: "I will say Zheng and I probably agree on Northera almost as much as we disagree. CHTP is in for a tough fight at the Jan. 14 panel because the Northera data are far from confidence inspiring," Feuerstein writes, referencing SA contributor Nick Zheng (see Zheng's recent article here).